Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.

Abstract

AIMS:

It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab (¹³¹I-rituximab).

METHODS:

Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of ¹³¹I-rituximab. Contrast-enhanced ¹⁸F-FDG PET/CT scans were performed before and after 1 month of RIT. Tumor sizes and maximum standardized uptake values (SUVmax) of scans were measured.

RESULTS:

Four of the 24 patients survived. High SUVmax in a pretreatment scan was found to be related to poorer overall survival (OS) and progression-free survival (p = 0.04 and 0.02, respectively). Furthermore, a large tumor size in a pretreatment scan was associated with poorer OS but not with progression-free survival (p < 0.01 and p = 0.07, respectively). By multivariate analyses, a high SUVmax, a large tumor size in a pretreatment scan and diffuse large B-cell lymphoma histology were significantly associated with poorer OS [p = 0.04/hazard ratio (HR) = 3.54, p < 0.01/HR = 5.52, and p = 0.02/HR = 3.38, respectively).

CONCLUSION:

SUVmax and tumor size determined by a pretreatment ¹⁸F-FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT.

• Authors: Ilhan Lim, Joon Yeun Park, Hye Jin Kang, Jae Pil Hwang, Seung Sook Lee, Kyeong Min Kim, Tae Hyun Choi, Sung Hyun Yang, Byung Il Kim, Chang Woon Choi, Sang Moo Lim
• Journal: Acta haematologica (Acta Haematol) Vol. 130 Issue 2 Pg. 74-82 ( 2013) ISSN: 1421-9662 [Electronic] Switzerland
• PMID: 23548464 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 S. Karger AG, Basel.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• Rituximab
• 131I-rituximab

Topics

• Adult
• Aged
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Disease-Free Survival
• Female
• Fluorodeoxyglucose F18 (therapeutic use)
• Humans
• Kaplan-Meier Estimate
• Lymphoma, Non-Hodgkin (mortality, pathology, radiotherapy)
• Male
• Middle Aged
• Multimodal Imaging
• Multivariate Analysis
• Neoplasm Staging
• Odds Ratio
• Positron-Emission Tomography
• Prognosis
• Radioimmunotherapy
• Radiopharmaceuticals (therapeutic use)
• Recurrence
• Rituximab
• Tomography, X-Ray Computed